Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Androderm Articles

Watson's 3rd-qtr 2007 revenue hits $594.7M

19 November 2007

Pharmacia & Paladin sign Canadian distribution deal

28 January 2002

Paladin acquires hyperthyroid drug from Merck Frosst

3 September 2001

Unimed files NDA for Androgel in USA

6 May 1999

Alza and Pharmagenesis launch Testoderm

15 October 1998

Alza's Testosterone Patch Approved

5 January 1998

US 2nd Qtr Corporate Results Round-Up

7 August 1997

SB Launches Androderm One-Patch In USA

19 June 1997

Alza To License Testosterone Product From Therapeutic Discovery Corp

10 February 1997

TheraTech Files sNDA For Androderm

4 November 1996

US Generic, Drug Delivery Firms Discuss Strategies

3 June 1996

US Corporate Quarterly Results Round-Up

13 May 1996

TheraTech's ATMOS Cleared In Sweden

15 April 1996

US Corporate Results Round-Up

26 February 1996

TheraTech/Solvay Collaborate On New HRT

6 November 1995

SmithKline Beecham Unveils Power Pipeline

9 October 1995

SB Expands Rights To Testosterone Patch

5 December 1994

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS